MedTrace Logo

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses

NCT00107965 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-03-25

No results posted yet for this study

Summary

The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of actinic keratoses.

Conditions

  • Actinic Keratosis

Interventions

DRUG

PEP005

0.0025% PEP005 Topical Gel (Day 1,2 application)

DRUG

PEP005

0.01% PEP005 Topical Gel (Day 1,2 application)

DRUG

PEP005

0.05% PEP005 Topical Gel (Day 1,2 application)

DRUG

PEP005

Vehicle Gel (Day 1,2 application)

DRUG

PEP005

0.0025% PEP005 Topical Gel (Day 1,8 application)

DRUG

PEP005

0.01% PEP005 Topical Gel (Day 1,8 application)

DRUG

PEP005

0.05% PEP005 Topical Gel (Day 1,8 application)

DRUG

PEP005

Vehicle Gel (Day 1,8 application)

Sponsors & Collaborators

  • Peplin

    lead INDUSTRY

Principal Investigators

  • Greg Siller

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2005-09-30
Completion
2005-09-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00107965 on ClinicalTrials.gov